Risk Materials

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

Keytruda (Pembrolizumab): Patient Alert Card

The provision of this card to patients is required by the terms of the Marketing Authorisation. Please ensure that you carry this card with you at all times and that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with pembrolizumab

Keytruda (pembrolizumab): Important safety information to minimise the risk of immune-related adverse reactions: Heathcare Professional Frequently Asked Questions

As part of the terms of the Marketing Authorisation for Keytruda, MSD are required to ensure that all Healthcare Professionals who are likely to treat patients with pembrolizumab are provided with risk minimisation materials This document contains key information to help minimize the risk of immune-mediated side-effects such as immune-related pneumonitis, colitis, hepatitis, nephritis, endocrinopathies (including hypophysitis, type 1 diabetes mellitus,(including diabetic ketoacidosis, hypothyroidism, hyperthyroidism, and thyroiditis)) and other immune-related adverse reactions, providing guidance on how to monitor and manage them. It also draws attention to the availability of the Patient Information Brochure and Patient Alert Card. If you require further information about pembrolizumab and hard copies of the material please contact [email protected] If you have any questions or require additional information, please call MSD Medical Information services on 01992 467272.

For Healthcare Professionals

Keytruda (pembrolizumab): Information for Patients Brochure: Important safety information to minimise the risk of immune-related adverse reactions

As part of the terms of the Marketing Authorisation for Keytruda, MSD are required to provide patients with information to help minimise the risk of immune-related adverse reactions that may occur with treatment with pembrolizumab. Please ensure that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with pembrolizumab.

Keytruda- explanatory note to RMM

Updated RMM were distributed to an agreed list of HCPs on 26 April 2018. This updates the product information for Keytruda with the risks of encephalitis, sarcoidosis and graft versus host disease (GVHD) after pembrolizumab administration in patients with a history of allogeneic hematopoietic stem cell transplant (HSCT)

Keytruda RMM- Dear HCP cover letter

Cover Letter accompanying updated RMM issued in April 2018 Reflects the update to the product information to include the risks of encephalitis, sarcoidosis and graft versus host disease (GVHD) after pembrolizumab administration in patients with a history of allogeneic hematopoietic stem cell transplant (HSCT)

For Healthcare Professionals

Send us feedback

If you would like to make a comment or send us feedback on this material, click here.